Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV Infection | Zendy

Luisa L. Villa | Zendy; Gonzalo Pérez | Zendy; Susanne Krüger Kjær | Zendy; Jorma Paavonen | Zendy; Matti Lehtinen | Zendy; Núbia Muñóz | Zendy; Kristján Sigurðsson | Zendy; Mauricio Hernández-Ávila | Zendy; Ole Eric Iversen | Zendy; Steinar Thoresen | Zendy; Patricia J. García | Zendy; Sławomir Majewski | Zendy; Hseon Tay Eng | Zendy; F. Xavier Bosch | Zendy; Joakim Dillner | Zendy; Sven Eric Olsson | Zendy; Kevin A. Ault | Zendy; Darron R. Brown | Zendy; Daron G. Ferris | Zendy; Laura A. Koutsky | Zendy; Robert J. Kurman | Zendy; Evan R. Myers | Zendy; Eliav Barr | Zendy; John W. Boslego | Zendy; Janine T. Bryan | Zendy; Mark T. Esser | Zendy; Teresa M. Hesley | Zendy; Micki Nelson | Zendy; Radha Railkar | Zendy; Margaret K. James | Zendy; Carlos A. Sattler | Zendy; Frank J. Taddeo | Zendy; Annemarie R. Thornton | Zendy; Scott Vuocolo | Zendy

Open Access

Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV Infection

Author(s) -

Luisa L. Villa,

Gonzalo Pérez,

Susanne Krüger Kjær,

Jorma Paavonen,

Matti Lehtinen,

Núbia Muñóz,

Kristján Sigurðsson,

Mauricio Hernández-Ávila,

Ole Eric Iversen,

Steinar Thoresen,

Patricia J. García,

Sławomir Majewski,

Hseon Tay Eng,

F. Xavier Bosch,

Joakim Dillner,

Sven Eric Olsson,

Kevin A. Ault,

Darron R. Brown,

Daron G. Ferris,

Laura A. Koutsky,

Robert J. Kurman,

Evan R. Myers,

Eliav Barr,

John W. Boslego,

Janine T. Bryan,

Mark T. Esser,

Teresa M. Hesley,

Micki Nelson,

Radha Railkar,

Margaret K. James,

Carlos A. Sattler,

Frank J. Taddeo,

Annemarie R. Thornton,

Scott Vuocolo

Publication year - 2007

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/522864

Subject(s) - medicine , vaccination , population , cervical cancer , genital warts , vaccine efficacy , hpv infection , hpv vaccines , disease , gynecology , immunology , cancer , environmental health

A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle (VLP) vaccine has been shown to be 95%-100% effective in preventing cervical and genital disease related to HPV-6, -11, -16, and -18 in 16-26-year-old women naive for HPV vaccine types. Because most women in the general population are sexually active, some will have already been infected with > or =1 HPV vaccine types at the time vaccination is offered. Here, we assessed whether such infected women are protected against disease caused by the remaining HPV vaccine types.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research